Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
ERNAW
ERNEXA THERAPEUTICS INC. WARRANTS
NASDAQ
$0.03
▲ UP 0.64% (0.00)

KEY STATISTICS

Market Cap$247.37 K
52w High$0.04
52w Low$0.03
Dividend Yield—
Frequency—
P/E—
Volume6.30K
Shares Out.7.85M

COMPANY

LEADERSHIP

Sanjeev Luther
CHIEF EXECUTIVE
Sanjeev Luther

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 12, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
5

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

PRICE

$0.03 ▲ UP 0.64% (+$0.00)
$0.03$0.03$0.04$0.04$0.042:13 PM2:13 PM2:13 PM2:13 PM2:13 PM2:13 PM2:14 PM0.03

About Ernexa Therapeutics Inc. Warrants

https://www.ernexatx.com ↗

Ernexa Therapeutics Inc., founded in 2018 in Cambridge, MA, develops allogenic iMSC therapies for solid tumors and autoimmune diseases, with lead products ERNA-101 for ovarian cancer and ERNA-102 for rheumatoid arthritis.

INDUSTRY

Biotechnology

A PRODUCT ERNEXA THERAPEUTICS INC. WARRANTS IS KNOWN FOR

ERNA-101
ERNA-101

ERNA-101, Ernexa Therapeutics' lead cell therapy targeting solid tumors like ovarian cancer, aims to enhance immune recognition and attack of cancer cells, with clinical trials underway.

COMPETITORS

COMPETITOR
BNTX COMPARE
FATE COMPARE
IPSC COMPARE
MRNA COMPARE
SANA COMPARE

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book5
Overall Score2